Agalsidase alfa clinical trials
Also written Replagal and DRX005B.
How each study uses agalsidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the agalsidase alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 3 Aug 2001 · Replagal · EMEA/H/C/000369 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2003 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 9
Shire (8) · National Institute of Neurological Disorders and Stroke (NINDS) (5) · University Hospital, Rouen (1) · Takeda (1) · Baylor Research Institute (1) · Rigshospitalet, Denmark (1) · Assistance Publique - Hôpitaux de Paris (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Agalsidase alfa is the comparator. A study of two new drugs counts under both.
- 1Venglustat · Sanofi
Reaching primary completion within a year · 1
Studies that test agalsidase alfa.
- Oct 2027A Study of Replagal in Children and Adults With Fabry Disease in IndiaPhase 4 · Shire
Studies
Open first, then newest update. How each study uses agalsidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- A Study of Replagal in Children and Adults With Fabry Disease in IndiaRecruitingPhase 4ShireNCT05067868Written as ReplagalHow we know
- Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry DiseaseCompletedNot applicableUniversity Hospital, RouenNCT02956954Written as Enzyme replacement therapy (Agalsidase alpha (Replagal®))How we know
- A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseaseCompletedPhase 3TakedaNCT04974749Written as REPLAGALHow we know
- A Study of Replagal in Treatment-naïve Adults With Fabry DiseaseTerminatedPhase 3ShireNCT04840667Written as REPLAGALHow we know
- Replagal Enzyme Replacement Therapy for Children With Fabry DiseaseCompletedPhase 2ShireNCT00084084Written as Agalsidase alfaHow we know
- This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.CompletedPhase 2ShireNCT01304277Written as agalsidase alfaHow we know
- Safety Study of Replagal® Therapy in Children With Fabry DiseaseCompletedPhase 2ShireNCT01363492Written as Replagal (agalsidase alfa)How we know
- Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry DiseaseCompletedPhase 3ShireNCT00864851Written as ReplagalHow we know
- A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry DiseaseCompletedPhase 3ShireNCT01298141Written as agalsidase alfaHow we know
- Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry DiseaseCompletedPhase 3ShireNCT01124643Written as ReplagalHow we know
- Dosing Study of Replagal in Patients With Fabry DiseaseCompletedPhase 2Baylor Research InstituteNCT00068107Written as ReplagalHow we know
- Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.CompletedPhase 4Rigshospitalet, DenmarkNCT01997489Written as Enzyme replacementHow we know
- An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry DiseaseCompletedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT00357786Written as ReplagalHow we know
- Alternative Dosing and Regimen of Replagal to Treat Fabry DiseaseCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00075244Written as ReplagalHow we know
- Replagal Enzyme Replacement Therapy for Adults With Fabry DiseaseCompletedPhase 4National Institute of Neurological Disorders and Stroke (NINDS)NCT00097890Written as Replagal (Agalsidase Alfa)How we know
- Alpha-Galactosidase A Replacement Therapy for Fabry DiseaseCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00048906Written as DRX005BHow we know
- An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry DiseaseCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00071877Written as ReplagalHow we know
- Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry DiseaseStatus unknownPhase 4Assistance Publique - Hôpitaux de ParisNCT00487630Written as recombinant alpha-galactosidase AHow we know
Given beside what is tested · 1 — agalsidase alfa is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with agalsidase alfa
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseActive, not recruitingPhase 3SanofiNCT05280548Written as Agalsidase alfaHow we know
- To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry DiseaseWithdrawnPhase 4SanofiNCT04143958Written as agalsidase alfaHow we know
Codes
What other systems call agalsidase alfa · ClinicalTrials.gg INT000931
- MeSH (NLM) C000627036agalsidase alfaConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2HLC17MX9GAGALSIDASE ALFAConfirmed FDA, NLM
- RxNorm 259351One source FDA
- NCI Thesaurus C74209Agalsidase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627036 | agalsidase alfa | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2HLC17MX9G | AGALSIDASE ALFA | Confirmed FDA, NLM |
| RxNorm | 259351 | — | One source FDA |
| NCI Thesaurus | C74209 | Agalsidase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.